The BRAF mutation, confirmed as the most common driver mutational event involved in PTC [6, 7], has been identified as a highly specific marker of thyroid cancer as the mutation occurs exclusively in thyroid malignancy rather than in benignancy [8, 9]. Here, BRAF is linked to thyroid cancer.